Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P3.03 - Poster Session 3 - Technology and Novel Development
- Type: Poster Session
- Track: Biology
- Presentations: 3
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.03-001 - The overxpression of TS protein induced by NPe6-PDT
09:30 - 09:30 | Author(s): S. Maehara
- Abstract
Loading... -
+
P3.03-002 - Heterogenity of Adeno carcinoma of Lung - change in Immunohistochemistry and histopathology chacter in patients treated with chemotherapy or EGFR-TKIs
09:30 - 09:30 | Author(s): G.S. Bhattacharyya
- Abstract
Loading... -
+
P3.03-003 - The relationship between fresh macroscopic appearance of tissue specimen by CT guided biopsy and its clinicopathological feature in 58 patients with NSCLC.
09:30 - 09:30 | Author(s): T. Nakai
- Abstract
Loading...
-
+
P3.04 - Poster Session 3 - Tumor Immunology
- Type: Poster Session
- Track: Biology
- Presentations: 4
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.04-001 - Combined adjuvant chemoimmunotherapy with CBDCA+GEM and autologous tumor lysate-transduced dendritic cell vaccinations in patients with operable NSCLC
09:30 - 09:30 | Author(s): K. Yasumoto
- Abstract
Loading... -
+
P3.04-002 - A phase II trial to assess the safety and immunological activity of Trovax plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - SKOPOS trial
09:30 - 09:30 | Author(s): J. Lester
- Abstract
Loading... -
+
P3.04-003 - High levels of circulating immunosuppressive cells predict worst clinical outcome in Non-Small Lung Cancer (NSCLC) patients
09:30 - 09:30 | Author(s): E.K. Vetsika
- Abstract
Loading... -
+
P3.04-004 - Interleukin-15: A potential factor in establishment and progression of lung cancer
09:30 - 09:30 | Author(s): J.C. Steel
- Abstract
Loading...
-
+
P3.05 - Poster Session 3 - Preclinical Models of Therapeutics/Imaging
- Type: Poster Session
- Track: Biology
- Presentations: 22
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.05-001 - Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6/STAT3 axis and EMT reversal
09:30 - 09:30 | Author(s): L. Li
- Abstract
Loading... -
+
P3.05-002 - Resistance to BH3 mimetic S1 in non-small cell lung cancer cells that phosphorylate Bim through ERK1/2 and lead to its proteasomal degradation
09:30 - 09:30 | Author(s): Y. Liu
- Abstract
Loading... -
+
P3.05-003 - Role of ATM in response of non-small cell lung cancer cell lines to therapeutic agents
09:30 - 09:30 | Author(s): A.A. Elegbede
- Abstract
Loading... -
+
P3.05-004 - Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) co-expressed with multidrug resistance 1 (MDR1) protein as new treatment approach in acquired cisplatin-resistance of malignant pleural mesothelioma and non-small cell lung cancercisplatin-resistance in a malignant mesothelioma cell line
09:30 - 09:30 | Author(s): P. Behnam Motlagh
- Abstract
Loading... -
+
P3.05-005 - Deregulation of Bcl-2 family protein expression and preserved post-target apoptosis resistance to the BH3-mimetic GX15-070 on acquisition of cisplatin-resistance in a malignant mesothelioma cell line
09:30 - 09:30 | Author(s): A. Tyler
- Abstract
Loading... -
+
P3.05-006 - Inhibition of Tumor Cell Growth, Migration by SIM-89, a Novel Inhibitor of c-Met Tyrosine Kinase
09:30 - 09:30 | Author(s): J. Pei
- Abstract
Loading... -
+
P3.05-007 - Epidermal Growth Factor Receptor Targeted Gold Nanoparticles for the Radiation Treatment of Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): R. Razzak
- Abstract
Loading... -
+
P3.05-008 - Novel anti-cancer properties of a MARCKS ED domain peptide occur through unique alterations of PI3K/AKT signaling
09:30 - 09:30 | Author(s): C. Chen
- Abstract
Loading... -
+
P3.05-009 - Metabolic Reprogramming Overcomes Resistance to ABT-737 -induced Apoptosis in Pre-clinical Models of Malignant Pleural Mesothelioma
09:30 - 09:30 | Author(s): X.M. Sun
- Abstract
Loading... -
+
P3.05-011 - Targeting epithelial to mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer
09:30 - 09:30 | Author(s): I. Cañadas
- Abstract
Loading... -
+
P3.05-012 - Potential Biomarkers of Growth Inhibition of Afatinib (BIBW-2992) in Combination with Dasatinib (BMS-354825) in Gefitinib Resistant Non Small Cell Lung Cancer Cells (NSCLC)
09:30 - 09:30 | Author(s): A.Y. Chang
- Abstract
Loading... -
+
P3.05-013 - Effect of PsA derivatives on DNA methyltransferase (DNMT) inhibition and radiosensitization in A549 lung cancer cell line
09:30 - 09:30 | Author(s): H.J. Kim
- Abstract
Loading... -
+
P3.05-014 - Eribulin, a tublin targeted chemotherapeutic agent, inhibits the in vitro growth of small cell lung cancer cell lines.
09:30 - 09:30 | Author(s): P. Bunn
- Abstract
Loading... -
+
P3.05-015 - Positron-emission tomography-computed tomography with the glucose analogue [18F] fluorodeoxyglucose in orthotopic implantation SCID mouse model of lung cancer
09:30 - 09:30 | Author(s): H. Takizawa
- Abstract
Loading... -
+
P3.05-016 - Effective combination therapies with MEK inhibitors for the treatment of mutant-BRAF lung cancers.
09:30 - 09:30 | Author(s): E. Matti
- Abstract
Loading... -
+
P3.05-017 - LKB1 loss induces characteristic pathway activation in human tumors and confers sensitivity to MEK inhibition due to attenuated PI3K-AKT-FOXO3 signaling.
09:30 - 09:30 | Author(s): J. Kaufman
- Abstract
Loading... -
+
P3.05-018 - Does elongation of treatment time in respiratory gated radiotherapy alter cell survivals?
09:30 - 09:30 | Author(s): S. Song
- Abstract
Loading... -
+
P3.05-019 - Bim expression in EGFR-mutant lung cancer 3D spheroids predicts responsiveness to tyrosine kinase inhibitors
09:30 - 09:30 | Author(s): H. Lee
- Abstract
Loading... -
+
P3.05-020 - Strategies for the prevention of mesothelioma in MexTAg mice
09:30 - 09:30 | Author(s): C. Robinson
- Abstract
Loading... -
+
P3.05-021 - Targeting HDACs to overcome cisplatin resistance in malignant plural mesothelioma
09:30 - 09:30 | Author(s): A. Baird
- Abstract
Loading... -
+
P3.05-022 - BMS-777607 as a candidate therapeutic agent in Malignant Pleural Mesothelioma
09:30 - 09:30 | Author(s): K. O'Byrne
- Abstract
Loading... -
+
P3.05-023 - Treatment with the mTOR kinase inhibitor CC-223 overcomes resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in non-small cell lung cancer cells
09:30 - 09:30 | Author(s): S. Ekman
- Abstract
Loading...
-
+
P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 53
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.06-001 - Serum Nesfatin-1 Level As A Biomarker In Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): B. Karagoz
- Abstract
Loading... -
+
P3.06-002 - RLIP76 expression is prognostic and predictive of chemotherapy benefit in resected NSCLC
09:30 - 09:30 | Author(s): D. Urban
- Abstract
Loading... -
+
P3.06-003 - Correlative Analysis of Circulating Biomarkers from a Phase 1b/2 trial of Cabozantinib (C) with or without Erlotinib (E) in Patients (Pts) with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): S.K. Padda
- Abstract
Loading... -
+
P3.06-004 - T790M Mutation in Patients with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Is It Associated with Clinically Distinct Features?
09:30 - 09:30 | Author(s): J.H. Ji
- Abstract
Loading... -
+
P3.06-005 - A Prospective Protocol for Simultaneous Genomic Testing in Patients with Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): F. Lopez-Rios
- Abstract
Loading... -
+
P3.06-006 - Integrated genomic analysis of EGFR-mutant non-small cell lung cancer immediately following erlotinib initiation in patients
09:30 - 09:30 | Author(s): P. Gianikopoulos
- Abstract
Loading... -
+
P3.06-007 - Clinical feasibility study of a novel sorting system for detecting EGFR mutations from captured circulating tumor cells in patients with lung cancer
09:30 - 09:30 | Author(s): T. Sawada
- Abstract
Loading... -
+
P3.06-008 - Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): D.W. Hwang
- Abstract
Loading... -
+
P3.06-009 - Paradoxical increase in Ki67 with neoadjuvant chemotherapy in NSCLC
09:30 - 09:30 | Author(s): G.J. Weiss
- Abstract
Loading... -
+
P3.06-011 - The impact of E-cadherin transcriptional factors on the survival of pulmonary pleomorphic carcinoma
09:30 - 09:30 | Author(s): S. Miyahara
- Abstract
Loading... -
+
P3.06-012 - Pharmacogenetic study of Japanese patients with advanced non-squamous non-small cell lung cancer treated with pemetrexed plus cisplatin
09:30 - 09:30 | Author(s): T. Takahashi
- Abstract
Loading... -
+
P3.06-013 - ICE COLD-PCR Combined with Next-Generation Sequencing: Increased Sensitivity for High Throughput Detection of Mutations.
09:30 - 09:30 | Author(s): K. Richardson
- Abstract
Loading... -
+
P3.06-014 - Positive prognostic impact of miR-210 in non-small cell lung cancer
09:30 - 09:30 | Author(s): M. Eilertsen
- Abstract
Loading... -
+
P3.06-015 - Integrated Prognosis in Early Stage Resectable Lung Adenocarcinoma
09:30 - 09:30 | Author(s): E. Kim
- Abstract
Loading... -
+
P3.06-016 - Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: identification of prognostic microenvironmental factors after chemoradiation
09:30 - 09:30 | Author(s): Y. Zenke
- Abstract
Loading... -
+
P3.06-017 - Distinctive Insulin-Like Growth Factor 1 gene copy number and protein expression in non-small cell lung cancer
09:30 - 09:30 | Author(s): T.N. Tran
- Abstract
Loading... -
+
P3.06-018 - ECT2 overexpression and gene alteration are associated with the outcome of early-stage lung adenocarcinoma
09:30 - 09:30 | Author(s): Y. Minami
- Abstract
Loading... -
+
P3.06-019 - MDM2 309T>G polymorphism and risk of lung cancer in a Japanese population
09:30 - 09:30 | Author(s): S. Kakegawa
- Abstract
Loading... -
+
P3.06-020 - Prognostic Markers for Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural pneumonectomy
09:30 - 09:30 | Author(s): B. Bitanihirwe
- Abstract
Loading... -
+
P3.06-021 - Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer
09:30 - 09:30 | Author(s): J.N. Jakobsen
- Abstract
Loading... -
+
P3.06-022 - Population based study of the prevalence of EGFR mutations in non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): B.G. Skov
- Abstract
Loading... -
+
P3.06-023 - Usefulness of Pleural Effusion for the Detection of EGFR Mutation by Using Direct Sequencing and PNA Clamping
09:30 - 09:30 | Author(s): S.J. Kim
- Abstract
Loading... -
+
P3.06-024 - Retrospective analysis of rebiopsies in a cohort of EGFR-mutated NSCLC-patients with TKI-resistance; incidence of the T790M mutation.
09:30 - 09:30 | Author(s): J.L. Kuiper
- Abstract
Loading... -
+
P3.06-025 - T790M mutation associated with better efficacy of continuous EGFR-TKI treatment in advanced NSCLC patients with acquired resistance to EGFR-TKI
09:30 - 09:30 | Author(s): S. Ren
- Abstract
Loading... -
+
P3.06-026 - Thymidylate synthase (TS) mRNA and protein expression in advanced non-small cell lung cancer (NSCLC) patients treated with pemetrexed-based therapy.
09:30 - 09:30 | Author(s): V. Monica
- Abstract
Loading... -
+
P3.06-027 - A comparison of FISH and immunohistochemistry in the detection of ALK rearrangement in lung adenocarcinoma
09:30 - 09:30 | Author(s): J. Le Quesne
- Abstract
Loading... -
+
P3.06-028 - Approach to Biomarker Testing: Perspectives from Various Specialties
09:30 - 09:30 | Author(s): N. Leighl
- Abstract
Loading... -
+
P3.06-029 - Predictive role of serum tumor markers in NSCLC patients treated with erlotinib
09:30 - 09:30 | Author(s): O. Fiala
- Abstract
Loading... -
+
P3.06-030 - Circulating tumor cells as a novel predictive marker in patients with advanced adenocarcinoma of the lung treated with platinum and pemetrexed
09:30 - 09:30 | Author(s): F. Grossi
- Abstract
Loading... -
+
P3.06-031 - mRNA and Splice Variant Analysis in Endobronchial Lining Fluid collected by Bronchoscopic Microsampling in Proximity of Pulmonary Nodules
09:30 - 09:30 | Author(s): N.C. Kahn
- Abstract
Loading... -
+
P3.06-032 - Evaluation of Anaplastic lymphoma kinase (ALK) rearrangements using ALK/EML4 TriCheck Fluorescence In Situ Hybridisation (FISH) in Non-Small Cell Lung Cancers (NSCLC) and its utility for equivocal cases.
09:30 - 09:30 | Author(s): C.I. Selinger
- Abstract
Loading... -
+
P3.06-033 - Subcellular localization of Nrf2 promotes tumor aggressiveness, poor outcome, and unfavorable response to chemotherapy via increased IKKβ stability in NSCLC
09:30 - 09:30 | Author(s): H. Lee
- Abstract
Loading... -
+
P3.06-034 - Dual-function protein APE1 is a novel biomarker to predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
09:30 - 09:30 | Author(s): Z. Li
- Abstract
Loading... -
+
P3.06-035 - Study of the correlations between SNPs in angiogenic genes and treatment response/ outcome in patients with advanced NSCLC (non-squamous histology) treated in first line with carboplatin, paclitaxel and bevacizumab (CPB). The ANGIOMET study.
09:30 - 09:30 | Author(s): B. Massuti
- Abstract
Loading... -
+
P3.06-036 - Prospective correlative study of FDG-PET SUV and proteomic profile (VeriStrat) of Non Small Cell Lung Cancer (NSCLC) patients treated with erlotinib
09:30 - 09:30 | Author(s): C. Lazzari
- Abstract
Loading... -
+
P3.06-037 - Expression of stemness factors OCT4 and NANOG in resectable non-small cell lung cancer.
09:30 - 09:30 | Author(s): R. Requena
- Abstract
Loading... -
+
P3.06-038 - New scoring system assessing the probability of malignancy as the cause of large pericardial effusion is able to improve the diagnostic algorithm of neoplastic pericarditis.
09:30 - 09:30 | Author(s): M. Szturmowicz
- Abstract
Loading... -
+
P3.06-039 - Expression of Mucin 1 in non-small cell lung cancer: Relationship between immunohistochemistry, tumour characteristics and survival
09:30 - 09:30 | Author(s): P.L. Mitchell
- Abstract
Loading... -
+
P3.06-040 - Characterization of PD-L1 expression and assessment of association with tumor histology and gene expression status in pretreatment non-small cell lung cancer (NSCLC) tumor specimens
09:30 - 09:30 | Author(s): C.T. Harbison
- Abstract
Loading... -
+
P3.06-041 - Serum miRNA signature predicts survival in patients with unresectable/inoperable non-small cell lung cancer treated with definitive radiation therapy
09:30 - 09:30 | Author(s): N. Bi
- Abstract
Loading... -
+
P3.06-042 - Pleural fluid ADA is associated with survival of patients with malignant pleural effusion
09:30 - 09:30 | Author(s): R.M. Terra
- Abstract
Loading... -
+
P3.06-043 - Modulation of the cyclooxygenase pathway is associated with efficacy in a randomized phase II trial of erlotinib and celecoxib or placebo in advanced non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): M.C. Fishbein
- Abstract
Loading... -
+
P3.06-044 - KRAS, EGFR mutations and EGFR gene copy status as predictive markers of response and time to progression in EGFR wild-type stage IV non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine-kinase inhibitors.
09:30 - 09:30 | Author(s): M. Domine
- Abstract
Loading... -
+
P3.06-045 - E-Cadherin and vimentin as biomarkers of clinical outcomes among EGFR+ lung adenocarcinoma (LA) patients treated with erlotinib (CLICaP)
09:30 - 09:30 | Author(s): A.F. Cardona
- Abstract
Loading... -
+
P3.06-046 - The tumor suppressor integrin-alpha 7 is frequently downregulated in malignant pleural mesothelioma: biological and prognostic consequences
09:30 - 09:30 | Author(s): M.A. Hoda
- Abstract
Loading... -
+
P3.06-047 - Prognostic value of neutrophil lymphocyte ratio in second line advanced malignant pleural mesothelioma
09:30 - 09:30 | Author(s): A. El Bastawisy
- Abstract
Loading... -
+
P3.06-048 - Progress with candidate predictive gene expression signatures for MEK inhibitors in non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): R. Brant
- Abstract
Loading... -
+
P3.06-049 - Detection of EGFR mutation in bronchial lavage fluid after transbronchial biopsy using a novel high-speed real-time PCR system.
09:30 - 09:30 | Author(s): T. Sakamoto
- Abstract
Loading... -
+
P3.06-050 - Characteristic Immunophenotype of Solid Subtype Component
in Lung Adenocarcinoma09:30 - 09:30 | Author(s): T. Takuwa
- Abstract
Loading... -
+
P3.06-051 - Circulating biomarkers may help guide selection of erlotinib versus chemotherapy in pretreated advanced NSCLC patients.
09:30 - 09:30 | Author(s): J.A. Borgia
- Abstract
Loading... -
+
P3.06-052 - A novel technique that distinguishes low-level somatic DNA variants from FFPE-induced artifacts in lung and other solid tumors by next-generation sequencing (NGS)
09:30 - 09:30 | Author(s): N. Udar
- Abstract
Loading... -
+
P3.06-053 - A diagnostic study to determine the prevalence of epidermal growth factor receptor (EGFR) mutations in Asian and Russian patients with non-small cell lung cancer (NSCLC) of adenocarcinoma and non-adenocarcinoma histology: IGNITE study design
09:30 - 09:30 | Author(s): B. Han
- Abstract
Loading... -
+
P3.06-054 - Development of a clinical-grade quantitative assay for non-invasive measurement of tumor genotype in cell-free plasma DNA (cfDNA) using next-generation quantitative genotyping
09:30 - 09:30 | Author(s): G.R. Oxnard
- Abstract
Loading...
-
+
P3.07 - Poster Session 3 - Surgery
- Type: Poster Session
- Track: Surgery
- Presentations: 48
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.07-001 - Long-term outcome and current problems of VATS versus open lobectomy for clinical stage IA non-small cell lung cancer
09:30 - 09:30 | Author(s): M. Higuchi
- Abstract
Loading... -
+
P3.07-002 - Pleural lymph flows exceeding the lung segment
09:30 - 09:30 | Author(s): Y. Watanabe
- Abstract
Loading... -
+
P3.07-003 - Functional Outcomes in Reconstruction of Massive Chest Wall Defects: A 17-Year Experience
09:30 - 09:30 | Author(s): M. Clemens
- Abstract
Loading... -
+
P3.07-004 - A novel soft-coagulation system for lung cancer surgery: minimization of surgeons' risk
09:30 - 09:30 | Author(s): A. Uchiyama
- Abstract
Loading... -
+
P3.07-005 - Recurrence-free and post-recurrence survival and the incidence of metachronous primary lung cancer after complete resection of non-small cell lung cancer
09:30 - 09:30 | Author(s): C. Endo
- Abstract
Loading... -
+
P3.07-006 - Robotic Assisted Lobectomy: A platform for increasing minimally invasive pulmonary resections
09:30 - 09:30 | Author(s): P. Ross
- Abstract
Loading... -
+
P3.07-007 - Induction treatment for locally advanced lung cancer deteriorates pulmonary function
09:30 - 09:30 | Author(s): H. Niwa
- Abstract
Loading... -
+
P3.07-008 - Surgery of non-small cell lung cancer in the elderly, comparison between 75-79 years old cases and 80 years or older cases
09:30 - 09:30 | Author(s): O. Kawamata
- Abstract
Loading... -
+
P3.07-009 - Combined use of virtual puncture by simulator with methylene blue stain localization of the pulmonary peripheral nodules
09:30 - 09:30 | Author(s): Y. Shen-Tu
- Abstract
Loading... -
+
P3.07-010 - Thoracoscopic Pneumonectomy - An 11 year experience
09:30 - 09:30 | Author(s): T.L. Demmy
- Abstract
Loading... -
+
P3.07-011 - Prognostic and predictive factors for recurrence-free survival in patients with completely resected pN2 non-small cell lung cancer
09:30 - 09:30 | Author(s): H. Uehara
- Abstract
Loading... -
+
P3.07-012 - Pulmonary Resection for Stage I Non-Small Cell Lung Cancer in Elderly Patients
09:30 - 09:30 | Author(s): B. Park
- Abstract
Loading... -
+
P3.07-013 - Chylothorax Complicating Video-assisted Thoracoscopic Pulmonary Resection in Non-small Cell Lung Cancer
09:30 - 09:30 | Author(s): C. Liu
- Abstract
Loading... -
+
P3.07-014 - Post-recurrence survival of surgically resected non-small cell lung cancer patients in the era of EGFR-TKI
09:30 - 09:30 | Author(s): Y. Matsumura
- Abstract
Loading... -
+
P3.07-015 - Robotic-Assisted Pulmonary Resection for Non-Small Cell Lung Cancer in High Risk Veteran Population: A Single Institution Experience
09:30 - 09:30 | Author(s): A. Abolhoda
- Abstract
Loading... -
+
P3.07-016 - Clinical Impact of Postoperative Cardio-pulmonary Complications on Long-term Outcome in Lung Cancer Patients
09:30 - 09:30 | Author(s): T. Nojiri
- Abstract
Loading... -
+
P3.07-017 - Examination of the Surgical Procedures for Metastatic Pulmonary Tumors (Confirmation of the tumor local existence by the palpation)
09:30 - 09:30 | Author(s): S. Fujino
- Abstract
Loading... -
+
P3.07-018 - Assessing Survival and Grading the Severity of Complications in Octogenarians Undergoing Pulmonary Lobectomy
09:30 - 09:30 | Author(s): E.N. McKeown
- Abstract
Loading... -
+
P3.07-019 - Sex-Based Differernces in Morbidity and Mortality Associated with Non-Small Cell Lung Cancer Resections
09:30 - 09:30 | Author(s): A. Pendleton
- Abstract
Loading... -
+
P3.07-020 - Nonintubated Thoracoscopic Lobectomy for Lung Cancer: Experience of Two Medical Centers from Taiwan and China
09:30 - 09:30 | Author(s): M. Hung
- Abstract
Loading... -
+
P3.07-021 - Pulmonary Metastasis, Particularly of Sarcomas, Amenable to Aggressive Surgical Management
09:30 - 09:30 | Author(s): J.A. Reza
- Abstract
Loading... -
+
P3.07-022 - Preoperative lipiodol marking for small-sized lung tumors
09:30 - 09:30 | Author(s): J. Shimada
- Abstract
Loading... -
+
P3.07-023 - Changes in Symptom Occurrence Rates and Severity Ratings Before and Following Lung Cancer Surgery
09:30 - 09:30 | Author(s): T. Oksholm
- Abstract
Loading... -
+
P3.07-024 - The endo-finger technique for the localization of small pulmonary ground glass nodules under thoracoscopic surgery
09:30 - 09:30 | Author(s): K. Sakamoto
- Abstract
Loading... -
+
P3.07-025 - Preoperative physiologic assessment of lung cancer surgery using the modified ACCP guidelines
09:30 - 09:30 | Author(s): T. Nakagawa
- Abstract
Loading... -
+
P3.07-026 - A non-interventional study on EGFR mutation status and clinical outcomes of Chinese patients with completely resected lung adenocarcinoma (ICAN study)
09:30 - 09:30 | Author(s): Y. Wu
- Abstract
Loading... -
+
P3.07-027 - Risk factors and outcome of pneumonectomy in lung cancer patients
09:30 - 09:30 | Author(s): M. Wong Jaen
- Abstract
Loading... -
+
P3.07-028 - Long-term result of robot-assisted esophagectomy for esophageal cancer: Technical feasibility and oncological reliability.
09:30 - 09:30 | Author(s): C. Kang
- Abstract
Loading... -
+
P3.07-029 - Clinicopathological Features of Resected Subcentimeter Lung Cancer
09:30 - 09:30 | Author(s): H. Sakurai
- Abstract
Loading... -
+
P3.07-030 - Surgical treatment of bronchopulmonary carcinoid tumors - a single institution experience
09:30 - 09:30 | Author(s): P. Rudzinski
- Abstract
Loading... -
+
P3.07-031 - Surgical Outcome of Resected Lung Cancer Patients Complicated with Combined Pulmonary Fibrosis and Emphysema
09:30 - 09:30 | Author(s): M. Fukui
- Abstract
Loading... -
+
P3.07-032 - Systemic extended bilateral mediastinal lymph node dissection through a median sternotomy with non-small cell carcinoma of the right upper lobe.
09:30 - 09:30 | Author(s): T. Yokota
- Abstract
Loading... -
+
P3.07-033 - Surgical treatments for NSCLC of female patients under 50 years old
09:30 - 09:30 | Author(s): R. Kaku
- Abstract
Loading... -
+
P3.07-034 - Therapeutic outcomes in 24 cases of postoperative bronchopleural fistula in lung cancer surgery
09:30 - 09:30 | Author(s): K. Imai
- Abstract
Loading... -
+
P3.07-035 - Benefit of preoperative localization using fragmented platinum microcoil for fluoroscopy-aided thoracoscopic resection of solitary pulmonary nodules
09:30 - 09:30 | Author(s): D.G. Cho
- Abstract
Loading... -
+
P3.07-036 - Postrecurrence survival of surgically resected pulmonary adenocarcinoma patients according to EGFR and KRAS mutation status
09:30 - 09:30 | Author(s): Y. Ohtaki
- Abstract
Loading... -
+
P3.07-037 - A Systematic Review and Meta-analysis on Pulmonary Resections by Robotic Video-Assisted Thoracic Surgery
09:30 - 09:30 | Author(s): C. Cao
- Abstract
Loading... -
+
P3.07-038 - Long-term outcome after resection of non-small cell lung cancer invading the thoracic inlet
09:30 - 09:30 | Author(s): S. Collaud
- Abstract
Loading... -
+
P3.07-039 - Video-assisted mediastinoscopic lymphadenectomy is associated with better survival than mediastinsocopy in patients with operable and inoperable non-small cell lung cancer patients.
09:30 - 09:30 | Author(s): A. Turna
- Abstract
Loading... -
+
P3.07-040 - Temporal trends in surgical outcomes for early stage non-small cell lung cancer
09:30 - 09:30 | Author(s): B.M. Robinson
- Abstract
Loading... -
+
P3.07-041 - Study on surgical cases for simultaneous multiple GGNs in bilateral lung
09:30 - 09:30 | Author(s): H. Ishida
- Abstract
Loading... -
+
P3.07-042 - Prophylactic landiolol administration can prevent atrial fibrillation after lobectomy?
09:30 - 09:30 | Author(s): K. Kajiura
- Abstract
Loading... -
+
P3.07-043 - Pneumonectomy, bronchoplasty, pulmonary arterioplasty, and combined resections of the superior vena cava are feasible even in salvage surgery after treated lung cancer
09:30 - 09:30 | Author(s): Y. Tsushima
- Abstract
Loading... -
+
P3.07-044 - Systematic Nodal Dissection During Pulmonary Metastasectomy: Results of a Clinical Study
09:30 - 09:30 | Author(s): J. Dolezel
- Abstract
Loading... -
+
P3.07-045 - Thin-section computed tomography findings of lung adenocarinoma inherent with metastatic potential
09:30 - 09:30 | Author(s): K. Aokage
- Abstract
Loading... -
+
P3.07-046 - A Novel Technique For Palliating Recurrent Pleural Effusions With a Port-Accessed Tunneled Catheter
09:30 - 09:30 | Author(s): J. Friedberg
- Abstract
Loading... -
+
P3.07-047 - Developing thoracic surgery quality across a broad region of western United States: Thoracic Surgery Initiative (TSI)
09:30 - 09:30 | Author(s): J.R. Handy
- Abstract
Loading... -
+
P3.07-048 - VATS lobectomy for NSCLC in Germany - results of a nationwide survey
09:30 - 09:30 | Author(s): J. Bodner
- Abstract
Loading...
-
+
P3.08 - Poster Session 3 - Radiotherapy
- Type: Poster Session
- Track: Radiation Oncology + Radiotherapy
- Presentations: 28
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.08-001 - Feasibility of stereotactic body radiation therapy with concurrent chemotherapy for patients over 75 years old with Stage I non-small-cell lung cancer.
09:30 - 09:30 | Author(s): M. Kokubo
- Abstract
Loading... -
+
P3.08-002 - An evidence-based estimation of survival and local control benefit of radiotherapy for lung cancer
09:30 - 09:30 | Author(s): J. Shafiq
- Abstract
Loading... -
+
P3.08-003 - FDG-PET parameters as predictors for outcome in Non Small Cell Lung Cancer NSCLC treated with Stereotactic Ablative Radiotherapy (SABR) at the St James's Institute of Oncology
09:30 - 09:30 | Author(s): M. Alzouebi
- Abstract
Loading... -
+
P3.08-004 - Significance of low dose distribution in developing radiation pneumonitis after helical tomotherapy based hypofractionated radiotherapy for pulmonary metastases
09:30 - 09:30 | Author(s): C.S. Kay
- Abstract
Loading... -
+
P3.08-005 - IAEA RCA 6065: Improving access to stereotactic ablative body radiotherapy (SABR) for lung cancer patients in Asia.
09:30 - 09:30 | Author(s): F. Hegi-Johnson
- Abstract
Loading... -
+
P3.08-006 - Respiratory function changes after stereotactic ablative radiotherapy (SABR) in stage I non-surgical NSCLC: preliminary results from a single institution prospective study.
09:30 - 09:30 | Author(s): C. Ferrero
- Abstract
Loading... -
+
P3.08-007 - Stereotactic Ablative Radiotherapy (SABR) of Centrally Located Early Stage Lung Cancer Accrued to RTOG 0813: Novel Scoring System to Compare Plan Quality of Volumetric Modulated Arc Therapy (VMAT) versus Robotic Radiosurgery
09:30 - 09:30 | Author(s): V.J. Nair
- Abstract
Loading... -
+
P3.08-008 - Comparison of auto- segmented PET volumes in discrete Lung tumors with CT based manual contours: Implications in radiotherapy planning.
09:30 - 09:30 | Author(s): M.R. Kanakamedala
- Abstract
Loading... -
+
P3.08-009 - Radiotherapy for postoperative thoracic lymph node recurrence in patients with non-small cell lung cancer without distant metastasis
09:30 - 09:30 | Author(s): J. Okami
- Abstract
Loading... -
+
P3.08-010 - The potential use of MRI to delineate lung cancer volumes for radiotherapy
09:30 - 09:30 | Author(s): S. Kumar
- Abstract
Loading... -
+
P3.08-011 - Stereotactic Ablative Radiotherapy: A Potentially Curable Approach to Multiple Primary Lung Cancer
09:30 - 09:30 | Author(s): J.Y. Chang
- Abstract
Loading... -
+
P3.08-012 - I-START Trial: A UK phase I/II trial of isotoxic accelerated radiotherapy in locally advanced non-small cell lung cancer
09:30 - 09:30 | Author(s): J. Lester
- Abstract
Loading... -
+
P3.08-013 - High local control rates with post-operative radiation therapy in incompletely resected non-small cell lung cancer (NSCLC) patients
09:30 - 09:30 | Author(s): S.U. Din
- Abstract
Loading... -
+
P3.08-014 - Very high radiation dose escalation in NSCLC does not lead to unexpected toxicity: A planned toxicity analysis of the PET-boost study (NCT01024829)
09:30 - 09:30 | Author(s): J. Van Diessen
- Abstract
Loading... -
+
P3.08-015 - Dosimetric factors associated with weight loss during radiotherapy treatment for non-small cell lung cancer
09:30 - 09:30 | Author(s): N. Kiss
- Abstract
Loading... -
+
P3.08-016 - Clinical outcome of [18F] FDG-PET/CT versus conventional CT based planning for radiotherapy in locally advanced NSCLC patients: a propensity-score matching study
09:30 - 09:30 | Author(s): W. Zhang
- Abstract
Loading... -
+
P3.08-017 - High-dose, conventionally fractionated thoracic reirradiation for second primary lung tumors or recurrent disease
09:30 - 09:30 | Author(s): G.H. Griffioen
- Abstract
Loading... -
+
P3.08-018 - Stereotactic body radiotherapy for oligometastatic disease to the lung
09:30 - 09:30 | Author(s): J. Ashman
- Abstract
Loading... -
+
P3.08-019 - Visual assessment of the presence of central photopenia on FDG-PET imaging in non-small cell lung cancer (NSCLC) and its prognostic influence on survival in patients treated with radiotherapy. A subset analysis of TROG 99.05.
09:30 - 09:30 | Author(s): T. Akhurst
- Abstract
Loading... -
+
P3.08-020 - Comparison of two Radiotherapy Planning Techniques for Stage IIIA and IIIB NSCLC: Hybrid Volumetric Modulated Arc Therapy (VMAT) vs 3D Conformal Radiotherapy (3D CRT)
09:30 - 09:30 | Author(s): K. Unicomb
- Abstract
Loading... -
+
P3.08-021 - Patient Specific Quality Assurance for Lung Cancer Stereotactic Ablative Body Radiotherapy
09:30 - 09:30 | Author(s): N. Hardcastle
- Abstract
Loading... -
+
P3.08-022 - Survival analysis of Hypo-fractionated Radical Radiotherapy for the treatment of Non-Small-Cell Lung Cancer using 55Gy in 20 fractions: The North Wales Cancer Centre Experience
09:30 - 09:30 | Author(s): N. Ghosal
- Abstract
Loading... -
+
P3.08-023 - Acute Esophagitis and concomittant Chemoradiotherapy with Navelbine. Results from NARLAL, a Phase II randomized Trial.
09:30 - 09:30 | Author(s): T. Schytte
- Abstract
Loading... -
+
P3.08-024 - Preliminary experience in bronchoscopic placement and in-treatment imaging of two different fiducial markers for guidance of lung cancer radiation.
09:30 - 09:30 | Author(s): D.P. Steinfort
- Abstract
Loading... -
+
P3.08-025 - Lung Tumors with Big Size or Irregular Shape or High-mobility can Better Benefit from Four-dimensional Radiotherapy
09:30 - 09:30 | Author(s): M. Chen
- Abstract
Loading... -
+
P3.08-026 - Factors Influencing One Year Survival in Radical Radiotherapy Treated Lung cancer Patients December 2010-November 2011, Beatson West Scotland Cancer Centre
09:30 - 09:30 | Author(s): H.W. Chemu
- Abstract
Loading... -
+
P3.08-027 - Radiation Pneumonitis in IMRT vs. 3D Conformal Radiation Therapy
09:30 - 09:30 | Author(s): M. Heskel
- Abstract
Loading... -
+
P3.08-028 - Impact of dosevolume parameters and clinical factors on severe acute radiation pneumonitis for lung cancer patients treated with concurrent chemo-radiotherapy
09:30 - 09:30 | Author(s): J. Wang
- Abstract
Loading...
-
+
P3.09 - Poster Session 3 - Combined Modality
- Type: Poster Session
- Track: Combined Modality
- Presentations: 18
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.09-001 - NSCLC in elderly patients with brain mets: Role of combined Erlotinib and Temozolomide with radiation therapy.
09:30 - 09:30 | Author(s): M.K. Behera
- Abstract
Loading... -
+
P3.09-002 - I want it all! The better outcome of patients with locally advanced non-small cell lung cancer receiving chemoradiation followed by surgery over any other combination of inductive chemotherapy, radiation or surgery
09:30 - 09:30 | Author(s): D. Marquez-Medina
- Abstract
Loading... -
+
P3.09-003 - Phase II study of nimotuzumab in combination with concurrent chemoradiotherapy (CRT) in patients with locally advanced non-small cell lung cancer (NSCLC).
09:30 - 09:30 | Author(s): K. Hayakawa
- Abstract
Loading... -
+
P3.09-004 - Oligometastatic non-small cell lung cancer: a simulation expert multidisciplinary tumor board.
09:30 - 09:30 | Author(s): C. Dooms
- Abstract
Loading... -
+
P3.09-005 - "Intention-to-treat" outcomes of sequential patients with stage IIIA lung adenocarcinomas treated with neoadjuvant chemotherapy with intent of surgical resection
09:30 - 09:30 | Author(s): M.D. Hellmann
- Abstract
Loading... -
+
P3.09-006 - Outcomes of Elderly Patients with Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Treated with Radiation +/- Chemotherapy at the Ottawa Hospital Cancer Centre
09:30 - 09:30 | Author(s): B.D. Healy
- Abstract
Loading... -
+
P3.09-007 - Update data of biomarker analysis of WJOG4107 (A randomized phase II trial of adjuvant chemotherapy with S-1 versus CDDP+S-1 for resected stage II-IIIA non-small cell lung cancer (NSCLC))
09:30 - 09:30 | Author(s): H. Tada
- Abstract
Loading... -
+
P3.09-008 - Prognosis of Stage III Non-Small Cell Lung Cancer Patients Initially Presenting with Superior Vena Cava Syndrome Treated with Partially Accelerated Definitive Concurrent Chemoradiotherapy
09:30 - 09:30 | Author(s): E. Topkan
- Abstract
Loading... -
+
P3.09-009 - Survival Outcome in Stage IIIB Non-Small Cell Lung Cancer Patients Younger than 45 Years: Retrospective Analysis of 145 Patients.
09:30 - 09:30 | Author(s): E. Topkan
- Abstract
Loading... -
+
P3.09-010 - Long Treatment Duration is Associated with Poor Prognosis in Patients Receiving Concurrent Chemoradiotherapy with The Diagnosis of Stage IIIB Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): E. Topkan
- Abstract
Loading... -
+
P3.09-011 - Concurrent chemoradiation for locally advanced Non Small Cell
Lung cancer (NSCLC) using weekly Cisplatin and Docetaxel:
retrospective analysis of toxicity and survival data .09:30 - 09:30 | Author(s): P. Baghi
- Abstract
Loading... -
+
P3.09-012 - A decade of community-based outcomes of patients treated with curative radiotherapy (RT) +/- chemotherapy for Non-Small Cell Lung Cancer (NSCLC).
09:30 - 09:30 | Author(s): A. Pramana
- Abstract
Loading... -
+
P3.09-013 - Outcomes and predictors for recurrence and survival after neoadjuvant concurrent chemoradiation followed by operation in patients with clinical stage III-N2 non-small-cell lung cancer
09:30 - 09:30 | Author(s): H. Lim
- Abstract
Loading... -
+
P3.09-014 - Concurrent chemoradiotherapy for patients with unresectable stage III non-small cell lung carcinoma; A real-life experience
09:30 - 09:30 | Author(s): U. Yilmaz
- Abstract
Loading... -
+
P3.09-015 - The role of adjuvant treatment in N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiation followed by surgery: A retrospective single center experience.
09:30 - 09:30 | Author(s): J.Y. Hong
- Abstract
Loading... -
+
P3.09-016 - A phase II study of cisplatin and oral vinorelbine concomitantly with radiotherapy in locally advanced non-small-cell lung cancer treatment: Eficacy and safety results.
09:30 - 09:30 | Author(s): O. Juan
- Abstract
Loading... -
+
P3.09-017 - Concurrent Chemoradiotherapy (ConCRT) using Cisplatin-Vinorelbine in Locally Advanced (LA) Non-small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): H. Charalambous
- Abstract
Loading... -
+
P3.09-018 - IFCT-0803 Trial: a phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC): preliminary safety analysis
09:30 - 09:30 | Author(s): J. Tredaniel
- Abstract
Loading...
-
+
P3.10 - Poster Session 3 - Chemotherapy
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 55
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.10-001 - Transglutaminase 2 can be predictive of epidermal growth factor receptor tyrosine kinase inhibitor efficacy and cytotoxic chemotherapy success in non-small cell lung cancer
09:30 - 09:30 | Author(s): J. Jeong
- Abstract
Loading... -
+
P3.10-002 - Resource utilization of NSCLC patients receiving platinum-based therapies across Europe; results from the FRAME observational study
09:30 - 09:30 | Author(s): D. Moro-Sibilot
- Abstract
Loading... -
+
P3.10-003 - A randomized Phase 2 trial of pemetrexed (P) and gefitinib (G) versus G as first-line treatment for patients with stage IV non-squamous (NS) non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
09:30 - 09:30 | Author(s): T. Puri
- Abstract
Loading... -
+
P3.10-004 - Jaw Osteonecrosis in lung cancer patients: a retrospective analysis
09:30 - 09:30 | Author(s): K.N. Syrigos
- Abstract
Loading... -
+
P3.10-005 - A Phase II Study of Amrubicin and Carboplatin for Previously Untreated Patients with Extensive-Disease Small Cell Lung Cancer
09:30 - 09:30 | Author(s): H. Taniguchi
- Abstract
Loading... -
+
P3.10-006 - Post-progression survival after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor for advanced non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
09:30 - 09:30 | Author(s): Y. Kogure
- Abstract
Loading... -
+
P3.10-007 - Avastin® for advanced or recurrent non-squamous non-small cell lung cancer: A nested case control study exploring risk factors for hemoptysis in Japan
09:30 - 09:30 | Author(s): K. Goto
- Abstract
Loading... -
+
P3.10-008 - A phase I study evaluating the continuation of gefitinib beyond progressive disease followed by the addition of docetaxel
09:30 - 09:30 | Author(s): S. Watanabe
- Abstract
Loading... -
+
P3.10-009 - Phase II study of bevacizumab in combination with carboplatin plus paclitaxel as first-line chemotherapy for non-squamous non-small cell lung cancer with malignant pleural effusion
09:30 - 09:30 | Author(s): A. Tamiya
- Abstract
Loading... -
+
P3.10-010 - A Study of Pemetrexed monotherapy in Patients with Advanced Non-Small Cell Lung Cancer with Impaired Renal Function
09:30 - 09:30 | Author(s): N. Funaguchi
- Abstract
Loading... -
+
P3.10-011 - Which do patients prefer as a first-line therapy, EGFR-TKI or chemotherapy, if they have NSCLC harboring EGFR mutation? A Vignettes study (LOGIK0903).
09:30 - 09:30 | Author(s): N. Ebi
- Abstract
Loading... -
+
P3.10-012 - Feasibility study of docetaxel and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
09:30 - 09:30 | Author(s): M. Yomota
- Abstract
Loading... -
+
P3.10-013 - Open-label, randomized multicentre, phase II trial of Oral vinorelbine (NVBo) or intravenous vinorelbine (NVBiv) with cisplatin (CDDP) in patients (pts) with advanced Non Small Cell Lung Cancer (NSCLC): A Chinese experience (CA225 study)
09:30 - 09:30 | Author(s): L. Zhang
- Abstract
Loading... -
+
P3.10-014 - Efficacy and Safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic Non-small-cell Lung Cancer
09:30 - 09:30 | Author(s): Y. Kim
- Abstract
Loading... -
+
P3.10-015 - Final analysis of dose escalation study of carboplatin plus pemetrexed followed by maintenance pemetrexed for elderly patients (≥75 years old) with advanced non-squamous non-small cell lung cancer
09:30 - 09:30 | Author(s): M. Tamiya
- Abstract
Loading... -
+
P3.10-016 - A phase I/II study of combination chemotherapy with erlotinib and S-1 in pretreated Non-Small Cell Lung Cancer (NSCLC): Thoracic Oncology Research Group (TORG) 0808/0913
09:30 - 09:30 | Author(s): N. Nogami
- Abstract
Loading... -
+
P3.10-017 - The role of cytokeratin fragment antigen 21-1 ( CYFRA21-1 ) as a predictive marker for the patients with non-small-cell lung cancer treated with pemetrexed
09:30 - 09:30 | Author(s): H. Minemura
- Abstract
Loading... -
+
P3.10-018 - An administration timing and dosage of the gefitinib in the advanced non-small-cell lung cancer patients with epidermal growth factor receptor mutation
09:30 - 09:30 | Author(s): S. Fujimoto
- Abstract
Loading... -
+
P3.10-019 - Oral S-1 and carboplatin followed by maintenance S-1 for chemo-naive patients with advanced squamous cell lung cancer (OSAKA-LCSG 1102)
09:30 - 09:30 | Author(s): T. Shiroyama
- Abstract
Loading... -
+
P3.10-020 - Phase I and Pharmacokinetic Study of Erlotinib Administered in Combination With Amrubicin in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): S. Otani
- Abstract
Loading... -
+
P3.10-021 - Phase II Multicenter Trial of Erlotinib for Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations
09:30 - 09:30 | Author(s): K. Isobe
- Abstract
Loading... -
+
P3.10-022 - Efficacy and safety of bevacizumab-based therapy in advanced non-squamous non small cell lung cancer : A retrospective study.
09:30 - 09:30 | Author(s): K. Ito
- Abstract
Loading... -
+
P3.10-023 - Phase II study of Pemetrexed + Carboplatin as first line therapy for advanced non-squamous non-small cell lung cancer without EGFR Mutation. : CENTRAL JAPAN LUNG STUDY GROUP (CJLSG) 0906 TRIAL
09:30 - 09:30 | Author(s): T. Kimura
- Abstract
Loading... -
+
P3.10-024 - Phase II study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for non-squamous non-small cell lung cancer with EGFR Mutation: CENTRAL JAPAN LUNG STUDY GROUP (CJLSG) 0910 TRIAL
09:30 - 09:30 | Author(s): T. Kimura
- Abstract
Loading... -
+
P3.10-025 - Taxane-Platinum Induction Chemotherapy in Locoregionally Advanced Non-Small-Cell Lung Cancer: Outcomes and Prognostic Factors
09:30 - 09:30 | Author(s): H.Y. Lee
- Abstract
Loading... -
+
P3.10-026 - Outcomes of patients undergoing adjuvant platinum-vinorelbine chemotherapy for resected non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): A. Pender
- Abstract
Loading... -
+
P3.10-027 - Selection of patients with adenocarcinoma of the lung for Gefinitib by FDG PET metabolic response
09:30 - 09:30 | Author(s): J. Jo
- Abstract
Loading... -
+
P3.10-028 - Pathologic complete remission after induction chemotherapy and intercalated Erlotinib in EGFR-mutated adenocarcinoma stage IIIA: Case report.
09:30 - 09:30 | Author(s): F.-. Griesinger
- Abstract
Loading... -
+
P3.10-029 - Second line chemotherapy exposure in a German Cancer Society certified lung cancer center: single center experience of 3 years and relevance for maintenance therapy
09:30 - 09:30 | Author(s): F.-. Griesinger
- Abstract
Loading... -
+
P3.10-030 - A Phase II study of Pemetrexed/Carboplatin for Previously Untreated Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Analysis of the correlation between the Anti-Tumor Efficacy/Toxicity and SNPs of MTHFR.
09:30 - 09:30 | Author(s): T. Kasai
- Abstract
Loading... -
+
P3.10-031 - Comparative Study Between Belotecan/Cisplatin and Etoposide/Cisplatin (COMBAT) in Patients with Previously Untreated, Extensive Stage Small Cell Lung Cancer
09:30 - 09:30 | Author(s): I. Oh
- Abstract
Loading... -
+
P3.10-032 - Efficiency and safety of erlotinib in the second and the further lines of treatment for patients (caucasian etnic) with advanced, non-small-cell lung cancer in Eastern Slovakia.
09:30 - 09:30 | Author(s): I. Andrasina
- Abstract
Loading... -
+
P3.10-033 - Prognostic factors in stage III non-small cell lung cancer patients with postoperative brain metastases
09:30 - 09:30 | Author(s): M. Kakihana
- Abstract
Loading... -
+
P3.10-034 - Is loss of MGMT a therapeutic target in lung cancer?
09:30 - 09:30 | Author(s): H. Do
- Abstract
Loading... -
+
P3.10-035 - Usefulness of IHC for detection of the ALK-fusion gene in non-small cell lung cancer
09:30 - 09:30 | Author(s): E. Sugiyama
- Abstract
Loading... -
+
P3.10-036 - Afatinib in Platinum- and Gefitinib or Erlotinib-pretreated Patients with NSCLC. A single Institution experience in a compassionate-use-program
09:30 - 09:30 | Author(s): D.F. Heigener
- Abstract
Loading... -
+
P3.10-037 - Drug therapy for patients with brain metastases from non-small cell lung cancer.
09:30 - 09:30 | Author(s): D.R. Naskhletashvili
- Abstract
Loading... -
+
P3.10-038 - The efficacy and safety of Pemetrexed after the failure of gefitinib in patients with adenocarcinoma with EGFR mutation.
09:30 - 09:30 | Author(s): K. Kim
- Abstract
Loading... -
+
P3.10-039 - Impact of Xanthine oxidoreductase and BRCA1 on prognosis of advanced Non-small cell Lung cancer
09:30 - 09:30 | Author(s): S. Yalcin
- Abstract
Loading... -
+
P3.10-040 - Optimal Duration of Chemotherapy for Advanced Non-small Cell Lung Cancer. A prospective population-based audit.
09:30 - 09:30 | Author(s): F. Andleeb
- Abstract
Loading... -
+
P3.10-041 - Impact of a Comprehensive Geriatric Assessment on management strategies in elderly patients with advanced no small cell lung cancer (NSCLC): a polled analysis of two phase 2 prospective study of the GFPC group.
09:30 - 09:30 | Author(s): I. Borget
- Abstract
Loading... -
+
P3.10-042 - Cisplatin vs. Carboplatin-based Chemoradiotherapy in Elderly Patients with Unresected Stage III Non-small Cell Lung Cancer
09:30 - 09:30 | Author(s): J.P. Wisnivesky
- Abstract
Loading... -
+
P3.10-043 - nab-Paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): an economic analysis
09:30 - 09:30 | Author(s): D. Spigel
- Abstract
Loading... -
+
P3.10-044 - Overall Survival analysis results of TFINE Study (CTONG 0904): Different Dose Docetaxel plus Cisplatin as First-line Chemotherapy and Then Maintenance Therapy with Single Agent Docetaxel for Advanced non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): S. Lu
- Abstract
Loading... -
+
P3.10-045 - Combination chemotherapy with bevacizumab, docetaxel and carboplatin for chemotherapy-naive patients with non-squamous cell lung carcinoma: Phase II study.
09:30 - 09:30 | Author(s): M. Matsumoto
- Abstract
Loading... -
+
P3.10-046 - Patients with advanced non-small cell lung cancer(NSCLC) received multi-line treatments had better efficacy
09:30 - 09:30 | Author(s): X. Zhang
- Abstract
Loading... -
+
P3.10-047 - Weight Gain During First-line Chemotherapy for Locally Advanced and Metastatic Non-Small-Cell Lung Cancer is Associated With Improved Survival
09:30 - 09:30 | Author(s): I. Ferreira
- Abstract
Loading... -
+
P3.10-048 - Referral patterns in advanced non small lung cancer: Impact on delivery of treatment and survival in British Columbia
09:30 - 09:30 | Author(s): K. Noonan
- Abstract
Loading... -
+
P3.10-049 - Combination Chemotherapy and autophagy Inhibition with Hydroxychloroquine for Advanced Non-small Cell Lung Cancer
09:30 - 09:30 | Author(s): J. Aisner
- Abstract
Loading... -
+
P3.10-050 - Changes of pulmonary function after platinum based chemotherapy in small cell lung carcinoma
09:30 - 09:30 | Author(s): W. Ban
- Abstract
Loading... -
+
P3.10-051 - Change in Pulmonary function after chemotherapy is different between squamous cell carcinoma and adenocarcinoma of the lung
09:30 - 09:30 | Author(s): W. Ban
- Abstract
Loading... -
+
P3.10-052 - Taxane monotherapy in advanced EGFR mutation positive lung cancer:
A single institution experience09:30 - 09:30 | Author(s): C. Baik
- Abstract
Loading... -
+
P3.10-053 - Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients: toxicity report
09:30 - 09:30 | Author(s): R. Bordoni
- Abstract
Loading... -
+
P3.10-054 - Metastatic NSCLC Outcomes at a Single Canadian Institution Over a Decade
09:30 - 09:30 | Author(s): S. Otsuka
- Abstract
Loading... -
+
P3.10-055 - Long progressive free survival to paclitaxel and cisplatin in first line is associated with better response and progression free survival to docetaxel in second line in advanced non-small cell lung cancer
09:30 - 09:30 | Author(s): E.O. Macedo
- Abstract
Loading...
-
+
P3.11 - Poster Session 3 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 52
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.11-001 - Classification and regression tree analysis of patients with non-small-cell lung cancer treated with gefitinib after chemotherapy
09:30 - 09:30 | Author(s): H. Sun
- Abstract
Loading... -
+
P3.11-002 - New toxicity profile as radiological response marker in the context of mTOR therapy in advanced/metastatic non small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): J. Corral
- Abstract
Loading... -
+
P3.11-003 - The use of epidermal growth factor receptor tyrosine kinase inhibitors in treatment of advanced EGFR wild-type non-small cell lung cancer: a meta-analysis study
09:30 - 09:30 | Author(s): K.M. Wong
- Abstract
Loading... -
+
P3.11-004 - A Prospective Study of the Use of Circulating Markers as Predictors for Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment in Pulmonary Adenocarcinoma
09:30 - 09:30 | Author(s): Y. Chen
- Abstract
Loading... -
+
P3.11-005 - Randomized, open-label, multi-center study of Gefitinib dose-escalation (500mg/d versus 250mg/d) in advanced NSCLC patient achieved Stable Disease (SD) after one-month Gefitinib treatment
09:30 - 09:30 | Author(s): L. Zhang
- Abstract
Loading... -
+
P3.11-006 - Erlotinib (E) and Dovitinib (TKI258) (D) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC): A Significant Pharmacokinetic (PK) Interaction
09:30 - 09:30 | Author(s): M. Das
- Abstract
Loading... -
+
P3.11-007 - Preliminary safety results of MONET-A: A Prospective, Asian Phase 3, Randomized, Placebo-controlled, Double-blind Trial of the Investigational agent Motesanib in Combination with Paclitaxel and Carboplatin for Asian patients of Advanced Non-squamous Non-small Cell Lung Cancer
09:30 - 09:30 | Author(s): H. Yoshioka
- Abstract
Loading... -
+
P3.11-008 - Phase II study of metronomic chemotherapy (MC) with bevacizumab (B) in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC)
09:30 - 09:30 | Author(s): F. Robert
- Abstract
Loading... -
+
P3.11-009 - Tulung registry: data analysis of patients with non-squamous NSCLC (adenocarcinoma, large cell carcinoma) and PS 0-1 treated with erlotinib in second line setting
09:30 - 09:30 | Author(s): J. Roubec
- Abstract
Loading... -
+
P3.11-010 - Patterns of relapse and prognosis after crizotinib therapy failure in ALK+ Non-small cell lung cancer
09:30 - 09:30 | Author(s): N. Yanagitani
- Abstract
Loading... -
+
P3.11-011 - Serum albumin as a potential pharmacodynamic biomarker in patients treated with the anti-hepatocyte growth factor monoclonal antibody ficlatuzumab
09:30 - 09:30 | Author(s): W. Su
- Abstract
Loading... -
+
P3.11-012 - Epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung.
09:30 - 09:30 | Author(s): M. Ameratunga
- Abstract
Loading... -
+
P3.11-013 - Treatment with high-dose, weekly erlotinib in EGFR-mutated NSCLC-patients with extra-cranial progressive disease
09:30 - 09:30 | Author(s): J.L. Kuiper
- Abstract
Loading... -
+
P3.11-014 - Safety, pharmacokinetics, and activity of the anti-NaPi2b antibody-drug conjugate DNIB0600A: A Phase I study in patients with non-small cell lung cancer and platinum-resistant ovarian cancer
09:30 - 09:30 | Author(s): D. Gerber
- Abstract
Loading... -
+
P3.11-015 - An open label, dose escalation, phase I trial to evaluate the tolerability and antitumor activity of icotinib in patients with advanced non-small-cell lung cancer
09:30 - 09:30 | Author(s): J. Shentu
- Abstract
Loading... -
+
P3.11-016 - Using Statistical Models to Improve Phase II Study Designs
09:30 - 09:30 | Author(s): N.H. Enas
- Abstract
Loading... -
+
P3.11-017 - Observational post-authorization prospective study to characterize the incidence of EGFR positive mutation (M+) in advanced or metastatic non-small cell lung cancer (aNSCLC) patients (P) and their clinical management in Galicia (NCT01717105): A Galician Lung Cancer Group study (GGCP 048-10)
09:30 - 09:30 | Author(s): S. Vazquez
- Abstract
Loading... -
+
P3.11-018 - Clinical Response of Lung Cancer Patients to Autologous Dendritic Cell Vaccination: A Compilation of Cases from the Lung Center of the Philippines
09:30 - 09:30 | Author(s): M.T.A. Barzaga
- Abstract
Loading... -
+
P3.11-019 - Gefitinib efficacy in EGFR mutated Non Small Cell Lung Cancer (NSCLC) patients based on type of mutation: a study from the Galician Lung Cancer Group.
09:30 - 09:30 | Author(s): C. Senin
- Abstract
Loading... -
+
P3.11-020 - Epidermal growth factor receptor (EGFR) mutation analyses in tumor and plasma samples from a Phase IV, single-arm study of first-line gefitinib in Caucasian patients with EGFR mutation-positive, advanced non-small-cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): J. Douillard
- Abstract
Loading... -
+
P3.11-021 - Bevacizumab (B) (10 mg/Kg) in combination with Cisplatin (C) and Docetaxel (D) administered every 2 weeks in patients (p) with advanced non-squamous Non-Small Cell Lung Cancer (nsNSCLC): GGCP047/10 study.
09:30 - 09:30 | Author(s): M. Lázaro
- Abstract
Loading... -
+
P3.11-022 - Deep Vein Trombosis Among Lung Cancer Patients Using Wells' Score: A Single Institution Experience
09:30 - 09:30 | Author(s): E. Syahruddin
- Abstract
Loading... -
+
P3.11-023 - Comparative safety profile of afatinib in Asian and non-Asian patients with EGFR mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): L.V. Sequist
- Abstract
Loading... -
+
P3.11-024 - QUARTZ
Quality of Life after Treatment for Brain Metastases from Non-Small Cell Lung Cancer: An update on the UK Medical Research Council QUARTZ trial.09:30 - 09:30 | Author(s): P.M. Mulvenna
- Abstract
Loading... -
+
P3.11-025 - Prognostic and predictive role of KRAS mutations in patients with advanced Non Small Cell Lung Cancer treated with docetaxel or erlotinib as second line treatment in the Tailor trial
09:30 - 09:30 | Author(s): M.C. Garassino
- Abstract
Loading... -
+
P3.11-026 - Results from two Phase 3 randomized trials of enobosarm, selective androgen receptor modulator (SARM), for the prevention and treatment of muscle wasting in NSCLC.
09:30 - 09:30 | Author(s): J. Crawford
- Abstract
Loading... -
+
P3.11-027 - A randomised, open-label phase II trial of volasertib as monotherapy and in combination with standard dose pemetrexed compared with pemetrexed monotherapy in second-line non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): P.M. Ellis
- Abstract
Loading... -
+
P3.11-028 - Exploration of the relationship between neutrophil count and clinical consequences in patients with advanced non-small cell lung cancer (NSCLC) receiving selumetinib plus docetaxel: predicted effect of primary prophylactic GCSF
09:30 - 09:30 | Author(s): P.A. Jänne
- Abstract
Loading... -
+
P3.11-029 - The SELECT-1 study design: selumetinib in combination with docetaxel for second-line treatment of KRAS mutation-positive locally advanced or metastatic non-small cell lung cancer
09:30 - 09:30 | Author(s): P.A. Jänne
- Abstract
Loading... -
+
P3.11-030 - A phase I / II trial of the HDAC inhibitor belinostat in combination with erlotinib in patients with non-small cell lung cancer.
09:30 - 09:30 | Author(s): J.L. Andersen
- Abstract
Loading... -
+
P3.11-031 - The clinical importance of EGFR-testing in non-small cell lung cancer:
Three year experience from Karolinska University Hospital in Sweden09:30 - 09:30 | Author(s): S. Mindus
- Abstract
Loading... -
+
P3.11-032 - A pilot single institution study of autologous tumor autophagosome (DRibble) vaccination with docetaxel in patients (pts) with stage IV non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): R.E. Sanborn
- Abstract
Loading... -
+
P3.11-033 - Brain Metastasis Features and Association with Tumor EGFR mutation in Patients with Adenocarcinoma of the Lungs
09:30 - 09:30 | Author(s): Y. Luo
- Abstract
Loading... -
+
P3.11-034 - One-year follow-up of a Phase I/II study of a highly selective ALK inhibitor CH5424802/RO5424802 in ALK-rearranged advanced non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): A. Inoue
- Abstract
Loading... -
+
P3.11-035 - An Open Label Compassionate Use Programme of BIBW 2992/afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated with Erlotinib or Gefitinib in Korea
09:30 - 09:30 | Author(s): M.K. Choi
- Abstract
Loading... -
+
P3.11-036 - Comparison of Clinical Outcome between Gefitinib and Erlotinib treatment in patients with non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 or exon 21 mutations
09:30 - 09:30 | Author(s): S.H. Lim
- Abstract
Loading... -
+
P3.11-037 - A phase II study of sorafenib and metformin in patients with stage IV non-small cell lung cancer (NSCLC) with a KRAS mutation
09:30 - 09:30 | Author(s): W.W. Mellema
- Abstract
Loading... -
+
P3.11-038 - EGFR mutations in squamous NSCLC - prevalence and treatment results with EGFR tyrosine kinase inhibitors in Slovak Republic
09:30 - 09:30 | Author(s): P. Berzinec
- Abstract
Loading... -
+
P3.11-039 - Exploration of patient health status as measured by the generic preference-based questionnaire EQ-5D alongside the START trial of tecemotide (L-BLP25) in non-small cell lung cancer
09:30 - 09:30 | Author(s): M.A. Socinski
- Abstract
Loading... -
+
P3.11-040 - Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomized, double-blind, placebo-controlled phase 3 study in second-line advanced non-small cell lung cancer (NSCLC) patients
09:30 - 09:30 | Author(s): S. Novello
- Abstract
Loading... -
+
P3.11-041 - Treatment with crizotinib in patients with IV stage non-small cell lung cancer (NSCLC) with ALK translocation: a single institution experience.
09:30 - 09:30 | Author(s): S. Carnio
- Abstract
Loading... -
+
P3.11-042 - Molecular Inequality in the Treatment of Non-Small Cell Lung Cancer (NSCLC) and Implications for Clinical Trials
09:30 - 09:30 | Author(s): J. Naidoo
- Abstract
Loading... -
+
P3.11-043 - Survival of patients with advanced lung adenocarcinoma before and after approved use of Gefitinib in China: a comparative clinical study in a single center
09:30 - 09:30 | Author(s): Y. Liu
- Abstract
Loading... -
+
P3.11-044 - Clinical impact of EGFR mutation fraction and tumour cellularity in EGFR mutation positive NSCLC
09:30 - 09:30 | Author(s): P. Martin
- Abstract
Loading... -
+
P3.11-045 - EGFR-TKI after disease progression with central nervous system metastasis in advanced non-small cell lung cancer with EGFR mutations
09:30 - 09:30 | Author(s): K. Kasahara
- Abstract
Loading... -
+
P3.11-046 - ROS1 overexpression by immunohistochemistry in non-small cell lung cancer: clinical characteristics, natural history and potential new therapeutic target based on two Australian cases
09:30 - 09:30 | Author(s): B.T. Li
- Abstract
Loading... -
+
P3.11-047 - Factors associated with brain metastasis in metastatic non-small cell lung cancer
09:30 - 09:30 | Author(s): E. Browning
- Abstract
Loading... -
+
P3.11-048 - Cost-effectiveness analysis of crizotinib in metastatic ALK+ Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): G. Lopes
- Abstract
Loading... -
+
P3.11-049 - Afatinib in advanced pretreated NSCLC - a Canadian experience
09:30 - 09:30 | Author(s): B. Melosky
- Abstract
Loading... -
+
P3.11-050 - Sunitinib for the treatment of RET-translocated NSCLC: A case report
09:30 - 09:30 | Author(s): G. Pall
- Abstract
Loading... -
+
P3.11-051 - VEGFRs predict bevacizumab benefit in advanced non small cell lung cancer patients
09:30 - 09:30 | Author(s): K. Zhang
- Abstract
Loading... -
+
P3.11-052 - Phase II study of intermittent erlotinib (E) plus carboplatin (C), paclitaxel (P) and bevacizumab (B) as frontline treatment of patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC): AVAFAST Study.
09:30 - 09:30 | Author(s): M.A. Cobo Dols
- Abstract
Loading...
-
+
P3.12 - Poster Session 3 - NSCLC Early Stage
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 25
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.12-001 - Lung Krueppel-like factor KLF2 improve post-operative prognosis of lung adenocarcinoma correlation with chemokine receptor CCR7 and genetical mutations of p53.
09:30 - 09:30 | Author(s): M. Itakura
- Abstract
Loading... -
+
P3.12-002 - Prognostic significance of the lymph node involvement in stage II-N1 non-small cell lung cancer
09:30 - 09:30 | Author(s): S. Lu
- Abstract
Loading... -
+
P3.12-003 - Preoperative Management of NSCLC Patients With PET/CT N2 Positive Mediastinal Lymph Nodes
09:30 - 09:30 | Author(s): F. Kutluhan
- Abstract
Loading... -
+
P3.12-004 - A practice-based analysis to gauge the feasibility of genotype-directed induction therapy for stage III non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): J. Varon
- Abstract
Loading... -
+
P3.12-005 - Clinical Significance of preoperative arterial blood gas in patients with stage I non-small cell lung cancer
09:30 - 09:30 | Author(s): S. Mizuguchi
- Abstract
Loading... -
+
P3.12-006 - Clinical Significance of Ki67 Expression in Curatively Resected Non-small Cell Lung Cancer
09:30 - 09:30 | Author(s): H.K. Ahn
- Abstract
Loading... -
+
P3.12-007 - A clinical relevance of intraoperative pleural lavage cytology in non-small lung cancer
09:30 - 09:30 | Author(s): M. Saito
- Abstract
Loading... -
+
P3.12-008 - Variations in the Uptake of Practice Guideline Recommendations on Adjuvant Chemotherapy Use Following Surgical Resection in Ontario
09:30 - 09:30 | Author(s): W. Evans
- Abstract
Loading... -
+
P3.12-009 - Patterns of care in patients receiving adjuvant chemotherapy for resected non-small cell lung cancer (NSCLC) in South Western Sydney Local Health District (SWSLHD)
09:30 - 09:30 | Author(s): A. Tognela
- Abstract
Loading... -
+
P3.12-010 - Impact of parietal pleural invasion at adhesion sites of lung cancers and implications for prognosis in the 7th TNM classification
09:30 - 09:30 | Author(s): M. Mikubo
- Abstract
Loading... -
+
P3.12-011 - Survival in resectable T1 and T2 stage non-small cell lung cancer
09:30 - 09:30 | Author(s): R. Zapata Gonzalez
- Abstract
Loading... -
+
P3.12-012 - Clinical and prognostic implication of ALK and ROS1 rearrangement in never smoker with surgically resected lung adenocarcinoma
09:30 - 09:30 | Author(s): H.R. Kim
- Abstract
Loading... -
+
P3.12-013 - Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
09:30 - 09:30 | Author(s): G.H. Griffioen
- Abstract
Loading... -
+
P3.12-014 - Prognostic impact of lymphovascular invasion according to the tumor size in patients with pN0 non-small cell lung cancer
09:30 - 09:30 | Author(s): H. Tao
- Abstract
Loading... -
+
P3.12-015 - Surgery for Early Non-Small Cell Lung Cancer with Preoperative Erlotinib (SELECT): A Correlative Biomarker Study
09:30 - 09:30 | Author(s): A.G. Sacher
- Abstract
Loading... -
+
P3.12-016 - Frequency in EGFR, K-RAS, BRAF and ALK mutations in a cohort of cancers: ALK translocations are more frequently seen in advanced disease
09:30 - 09:30 | Author(s): E. Lim
- Abstract
Loading... -
+
P3.12-017 - The lack of impact of pre-operative PET on the risk, and pace, of subsequent failure following surgery for early stage non-small cell lung cancer?
09:30 - 09:30 | Author(s): M. Saynak
- Abstract
Loading... -
+
P3.12-018 - Examination of the influence that vessel invasion gives prognosis of Stage I non small-cell lung cancer and the treatment effect of adjuvant therapy for the vessel invasion-positive Stage I cases
09:30 - 09:30 | Author(s): K. Kojima
- Abstract
Loading... -
+
P3.12-019 - Feasibility and efficacy of radical local therapy for Oligo-Recurrence of NSCLC
09:30 - 09:30 | Author(s): R. Nakajima
- Abstract
Loading... -
+
P3.12-020 - Derailed analysis of lung cancer with scattered consolidation
09:30 - 09:30 | Author(s): K. Suzuki
- Abstract
Loading... -
+
P3.12-021 - The role of pentraxin 3, an acute phase protein, and of smoldering inflammation at the tumor site in lung cancer progression and prognosis. A clinicopathologic study
09:30 - 09:30 | Author(s): M.V. Infante
- Abstract
Loading... -
+
P3.12-022 - Patterns of disease recurrence and modality of detection following surgery for early stage lung cancer
09:30 - 09:30 | Author(s): J. Brown
- Abstract
Loading... -
+
P3.12-023 - International Tailored Chemotherapy Adjuvant Trial: ITACA Trial
09:30 - 09:30 | Author(s): S. Novello
- Abstract
Loading... -
+
P3.12-024 - A multi-center phase II randomized study of customized neoadjuvant therapy vs. standard chemotherapy (CT) in non-small cell lung cancer (NSCLC) patients with resectable stage IIIA (N2) disease (CONTEST trial)
09:30 - 09:30 | Author(s): F. Grossi
- Abstract
Loading... -
+
P3.12-025 - Survival in octogenarians with pathological stage I non-small cell lung cancer patients underwent complete resection
09:30 - 09:30 | Author(s): Y. Yu
- Abstract
Loading...
first
prev
